Patients with CLL have a lower risk of death from COVID-19 in the Omicron era
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 803 KB, PDF document
Previous studies have shown that patients with chronic lymphocytic leukemia (CLL) and coronavirus disease 2019 (COVID-19) have high mortality rates. Infection with the Omicron variant has been described as a milder disease course in the general population. However, the outcome for immunocompromised patients has not previously been reported. In a cohort of patients with CLL tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at hospital test sites in the time periods before and after dominance of the Omicron variant, rates of hospitalizations and intensive care unit admissions declined significantly, whereas 30-day mortality remained as high as 23% in the period with dominance of the Omicron sublineage BA.2 variant. However, for a larger population-based cohort of patients with CLL (including the hospital cohort), 30-day mortality was 2%. Thus, patients with CLL with close hospital contacts and, in particular, those >70 years of age with 1 or more comorbidities should be considered for closer monitoring and preemptive antiviral therapy upon a positive SARS-CoV-2 test.
Original language | English |
---|---|
Journal | Blood |
Volume | 140 |
Issue number | 5 |
Pages (from-to) | 445-450 |
Number of pages | 6 |
ISSN | 0006-4971 |
DOIs | |
Publication status | Published - 2022 |
Bibliographical note
Publisher Copyright:
© 2022 American Society of Hematology
Links
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122776/pdf/main.pdf
Final published version
ID: 323844906